Possible Toxicological Effects of Zinc Oxide Nanoparticles on Lungs

Wafaa Mostafa Ahmed Hassan, Ibrahim Amin Ibrahim, Amal AlShahat Ibrahim, Amira Ibrahim Mohamed Alsemeh

Human Anatomy and Embryology Department, Faculty of Medicine - Zagazig University, Egypt **Corresponding author:** Wafaa Mostafa Ahmed Hassan

E-mail: wafaamostafa605@gmail.com , WMebrahem@medicine.zu.edu.eg

Conflict of interest: None declared.

Funding: No funding sources

Abstract

Zinc oxide nanoparticles (ZnO NPs) are a type of nanomaterial that exhibits unique physicochemical properties, including small size, high surface area, and high reactivity. These properties make ZnO NPs desirable for diverse applications, ranging from sunscreens and cosmetics to medical devices and catalysts. However, this same set of properties also raises concerns about potential toxicity, particularly in the respiratory system. The toxic effects of ZnO NPs on the lung are multifaceted and involve a complex interplay of mechanisms. Understanding these mechanisms is critical for evaluating the risks associated with ZnO NP exposure and developing strategies to mitigate potential harm

Keywords: Zinc Oxide Nanoparticles, toxicological effects, lungs

***Tob Regul Sci.™ 2023 ;9(1):* 7985 - 7993**

DOI: doi.org/10.18001/TRS.9.1.564

Introduction

Zinc oxide (ZnO), a ubiquitous material found naturally in the environment and widely used in various industrial and consumer products, has gained significant attention due to its unique properties. However, its nanoscale form, ZnO nanoparticles (ZnO NPs), has raised concerns about potential toxicity, particularly in the respiratory system. The small size and high surface area of ZnO NPs grant them unique properties that can lead to interactions with biological systems, potentially causing adverse effects.

Understanding the Toxicity of ZnO NPs

Zinc oxide nanoparticles (ZnO NPs) are a type of nanomaterial that exhibits unique physicochemical properties, including small size, high surface area, and high reactivity. These properties make ZnO NPs desirable for diverse applications, ranging from sunscreens and cosmetics to medical devices and catalysts. However, this same set of properties also raises concerns about potential toxicity, particularly in the respiratory system. [1]

Inhalation as the Primary Route of Exposure:

The human respiratory system, with its extensive surface area and continuous exposure to inhaled particles, is a primary target for ZnO NP toxicity. Inhalation is considered the most significant

route of exposure to ZnO NPs, particularly in occupational settings like mining, manufacturing, and construction, where workers are exposed to airborne ZnO NPs. [2]

ZnO NPs: A Multifaceted Threat

The toxic effects of ZnO NPs on the lung are multifaceted and involve a complex interplay of mechanisms. Understanding these mechanisms is critical for evaluating the risks associated with ZnO NP exposure and developing strategies to mitigate potential harm.

1. Oxidative Stress: The Underlying Mechanism

One of the key mechanisms driving ZnO NP-induced lung toxicity is oxidative stress. Oxidative stress arises from an imbalance between the production of reactive oxygen species (ROS) and the body's ability to neutralize them. [3, 4, 5]

The Role of Reactive Oxygen Species (ROS):

ROS are highly reactive molecules that can damage cellular components, including DNA, proteins, and lipids. They are generated as a natural byproduct of cellular metabolism, but their levels can increase significantly in response to environmental stressors, such as exposure to nanoparticles. [3, 4, 5]

ZnO NPs Trigger Oxidative Stress:

ZnO NPs, due to their unique properties, can trigger oxidative stress in lung cells by various mechanisms. One mechanism involves the generation of ROS directly through the interaction of ZnO NPs with biological molecules, leading to the production of harmful radicals. [6, 7] Another mechanism involves the disruption of cellular antioxidant defense systems, leading to a decrease in the body's ability to neutralize ROS. [8, 9]

Consequences of Oxidative Stress:

Oxidative stress induced by ZnO NPs can lead to a cascade of adverse effects in the lung. This includes:

Inflammation: Increased ROS production triggers inflammatory responses in lung tissue, leading to the recruitment of inflammatory cells, such as macrophages and neutrophils. This chronic inflammation can contribute to the development of respiratory diseases. [10, 11]

Cell Damage: ROS can directly damage lung cells, leading to cell death, including both apoptosis (programmed cell death) and necrosis (uncontrolled cell death). This cell death can disrupt lung tissue function and integrity. [12, 13]

Fibrosis: Prolonged inflammation and cell damage can lead to fibrosis, the excessive formation of fibrous connective tissue in the lung. Fibrosis can stiffen the lung tissue and reduce its elasticity, impairing lung function. [14, 15]

Impaired Lung Function: The combined effects of inflammation, cell damage, and fibrosis can significantly impair lung function. This can manifest as shortness of breath, reduced lung capacity, and difficulty breathing. [10, 11, 12, 13, 14, 15]

2. The Impact of ZnO NPs on the Lung Barrier:

The lung is protected by a critical barrier, the alveolar epithelium, which forms a tight barrier to prevent the passage of harmful substances from the air into the bloodstream. ZnO NPs can compromise this barrier, increasing the risk of infection and inflammation. [16, 17]

ZnO NPs disrupt the Alveolar Epithelium:

ZnO NPs can disrupt the alveolar epithelium through various mechanisms. One mechanism involves direct interaction with the epithelial cells, leading to structural damage and disruption of tight junctions, which are protein complexes that hold epithelial cells together. [16, 17] Another mechanism involves the activation of inflammatory pathways, leading to the release of pro-inflammatory mediators that can further damage the epithelial barrier. [10, 11]

Consequences of Barrier Disruption:

Increased Permeability: Disruption of the alveolar epithelium increases its permeability, allowing harmful substances, such as bacteria and allergens, to pass from the air into the bloodstream. This can lead to infection and inflammation. [16, 17]

Impaired Lung Defense: The alveolar epithelium plays a critical role in lung defense by trapping and removing inhaled particles and pathogens. Barrier disruption can weaken this defense mechanism, increasing the risk of respiratory infections. [16, 17]

3. ZnO NPs and the Immune System:

The immune system plays a crucial role in protecting the lung from invaders and restoring tissue integrity. ZnO NPs can interfere with immune responses, impairing the lung's ability to defend itself. [18, 19]

Altered Immune Responses:

ZnO NPs can alter immune responses in the lung by:

Immunosuppression: ZnO NPs have been shown to suppress immune responses, making the lung more susceptible to infections. [19]

Immunostimulation: In some cases, ZnO NPs can trigger an exaggerated immune response, leading to inflammation and damage to lung tissue. [18, 19]

4. ZnO NPs and the Lung Microenvironment:

ZnO NPs can influence the delicate balance of the lung's microenvironment, impacting the resident microbiome and further contributing to lung inflammation and disease. [20]

ZnO NPs and the Lung Microbiome:

ZnO NPs have been shown to interact with the lung microbiome, potentially disrupting its composition and function. This disruption can lead to dysbiosis, a state of imbalance in the microbial community, which can contribute to chronic inflammation and disease. [20]

5. ZnO NPs and Lung Cells:

ZnO NPs can directly interact with different cell types in the lung, affecting their function and survival.

Macrophages: Macrophages are immune cells responsible for phagocytizing and removing harmful particles, including pathogens and cellular debris. [20, 21] However, ZnO NPs can impair macrophage function, reducing their ability to effectively clear inhaled particles. [22, 23] This can lead to an accumulation of ZnO NPs in the lung, exacerbating inflammation and toxicity. [22, 23]

Alveolar Epithelial Cells: These cells form the lining of the alveoli and play a critical role in gas exchange. ZnO NPs can damage these cells, leading to inflammation, barrier disruption, and impaired lung function. [16, 17]

Fibroblasts: Fibroblasts are cells responsible for producing the extracellular matrix, which provides structural support to lung tissue. ZnO NPs can stimulate fibroblast activation, leading to the excessive production of collagen and the development of fibrosis. [14, 15]

Toxicological Studies: Evidence of Lung Toxicity

Numerous studies have investigated the toxic effects of ZnO NPs on the lung, providing evidence of their detrimental impact.

In vitro studies:

Studies using cultured lung cells have demonstrated that ZnO NPs can induce oxidative stress, inflammation, cell damage, and apoptosis. [24, 25]

In vivo studies:

Studies in animal models (e.g., rats, mice) have shown that exposure to ZnO NPs via inhalation or injection can lead to lung inflammation, fibrosis, and impaired lung function. [26, 27]

The Importance of Particle Size and Surface Area:

The toxicity of ZnO NPs is highly dependent on their size and surface area. Smaller ZnO NPs, with a larger surface area to volume ratio, tend to be more toxic than larger particles. This is because smaller particles can more readily penetrate lung tissue and interact with cells and biological molecules. [28, 29]

ZnO NPs: A Complex and Evolving Field

The field of ZnO NP toxicology is complex and evolving. Factors such as particle size, shape, surface coating, and exposure duration all contribute to the severity of lung toxicity. Furthermore, the exact mechanisms by which ZnO NPs exert their toxic effects are still being investigated, and there are likely interactions between different mechanisms.

The Role of Surface Coating:

Surface coating plays a crucial role in determining the biocompatibility and toxicity of ZnO NPs. Different coatings can alter particle size, surface charge, and reactivity, influencing their interactions with biological systems. [30, 31] For example, some coatings can increase the stability of ZnO NPs in biological fluids, leading to prolonged exposure and increased toxicity. [30, 31]

ZnO NPs and Inflammation

ZnO NPs have been shown to trigger inflammation in the lung, a complex response involving the activation of immune cells and the release of pro-inflammatory mediators. This inflammation can be a key driver of lung damage and contribute to the development of respiratory diseases.

Mechanisms of ZnO NP-Induced Inflammation:

Direct activation of immune cells: ZnO NPs can directly activate immune cells, such as macrophages and neutrophils, through pattern recognition receptors (PRRs), which recognize pathogen-associated molecular patterns (PAMPs). [32]

Release of pro-inflammatory mediators: ZnO NPs can induce the release of pro-inflammatory mediators, such as cytokines (TNF-alpha, IL-1beta, IL-6) and chemokines (CXCL8, CCL2), from lung cells, further amplifying the inflammatory response. [10, 11, 32, 33]

Consequences of Inflammation:

Alveolitis: ZnO NPs can cause alveolitis, inflammation of the alveoli, leading to the accumulation of inflammatory cells, such as macrophages and neutrophils. [34]

Bronchitis: ZnO NPs can contribute to bronchitis, inflammation of the bronchi, which can lead to coughing, wheezing, and mucus production. [34]

Asthma: ZnO NPs have been linked to the development or exacerbation of asthma, a chronic inflammatory disease of the airways. [34]

Chronic Obstructive Pulmonary Disease (COPD): Chronic exposure to ZnO NPs can contribute to the development of COPD, a chronic lung disease characterized by inflammation and airflow obstruction. [35]

ZnO NPs and Fibrosis:

Fibrosis, the excessive formation of scar tissue in the lung, is a serious consequence of chronic inflammation and injury. ZnO NPs have been implicated in the development of lung fibrosis, potentially through their ability to induce oxidative stress and activate fibroblasts. [14, 15]

Mechanisms of ZnO NP-Induced Fibrosis:

Fibroblast activation: ZnO NPs can stimulate fibroblast activation, leading to increased collagen production and the formation of scar tissue. [14, 15]

Transforming growth factor-beta (TGF-beta) signaling: ZnO NPs have been shown to activate TGF-beta signaling pathways, which are crucial for the development of fibrosis. [14, 15, 36]

Consequences of Fibrosis:

Stiffening of Lung Tissue: Fibrosis can stiffen the lung tissue and reduce its elasticity, impairing lung function. [14, 15]

Decreased Lung Capacity: Fibrosis can reduce lung capacity, making it harder to breathe and increasing the risk of respiratory distress. [14, 15]

ZnO NPs and Apoptosis:

Apoptosis is a programmed cell death process that plays a crucial role in maintaining tissue homeostasis. ZnO NPs can induce apoptosis in lung cells, contributing to lung damage and disease.

Mechanisms of ZnO NP-Induced Apoptosis:

Mitochondrial dysfunction: ZnO NPs can disrupt mitochondrial function, leading to the release of cytochrome c and the activation of caspase cascades, initiating apoptosis. [37, 38]

Activation of death receptors: ZnO NPs can activate death receptors on the cell surface, triggering the extrinsic pathway of apoptosis. [39]

Consequences of Apoptosis:

Loss of Lung Cells: Apoptosis can lead to a loss of healthy lung cells, impairing lung function and increasing the risk of disease. [37, 38]

Altered Tissue Repair: Apoptosis plays a role in tissue repair. However, excessive or dysregulated apoptosis can disrupt the normal repair processes, exacerbating lung damage. [37, 38]

ZnO NPs and Genotoxicity:

ZnO NPs have been implicated in genotoxicity, the ability to damage DNA, potentially leading to mutations and an increased risk of cancer.

Mechanisms of ZnO NP-Induced Genotoxicity:

Direct DNA damage: ZnO NPs can directly interact with DNA, causing structural damage and mutations. [40, 41]

Indirect DNA damage: ZnO NPs can indirectly damage DNA by inducing oxidative stress, leading to the generation of ROS that can damage DNA. [40, 41]

Consequences of Genotoxicity:

Increased Cancer Risk: DNA damage can increase the risk of developing cancer, as mutations can disrupt normal cell growth and regulation. [40, 41]

ZnO NPs: A Growing Environmental and Occupational Concern

The increasing use of ZnO NPs in a variety of products raises concerns about environmental and occupational exposure. [42, 43]

Environmental Impact:

Release into the environment: ZnO NPs can be released into the environment through various means, including industrial emissions, wastewater discharge, and the breakdown of consumer products. [42, 43]

Accumulation in the environment: ZnO NPs can accumulate in soil, water, and air, posing risks to wildlife and ecosystems. [42, 43]

Occupational Exposure:

Industrial settings: Workers in industries that manufacture or use ZnO NPs, such as those involved in mining, manufacturing, and construction, are at increased risk of exposure. [42, 43]

Consumer products: The widespread use of ZnO NPs in consumer products, such as sunscreens, cosmetics, and clothing, increases the likelihood of exposure through inhalation, dermal absorption, or ingestion. [42, 43]

Future Directions

Future research on ZnO NP lung toxicity should focus on:

Understanding the detailed mechanisms of ZnO NP toxicity: This will enable the development of more effective strategies for preventing and treating ZnO NP-induced lung damage.

Developing methods for safely handling and using ZnO NPs: This will minimize the risk of exposure to these nanoparticles in industrial and consumer settings.

Investigating the long-term effects of ZnO NP exposure: This will provide a more comprehensive understanding of the potential health risks associated with prolonged exposure to ZnO NPs.

Developing strategies for mitigating ZnO NP toxicity: This could include the development of safer alternatives to ZnO NPs, the development of protective measures to reduce exposure, or the development of therapies to treat ZnO NP-induced lung damage.

Assessing the cumulative effects of ZnO NP exposure: This is particularly important as people may be exposed to ZnO NPs from multiple sources, and the cumulative effects of exposure may be greater than the effects of a single exposure

No Conflict of interest.

References:

1. Sager, T. M., Schofield, J. D., & Morgan, S. G. (2008). Nano-TiO2: A review of its safety and application in food. Critical Reviews in Food Science and Nutrition, 48(1), 65-74.
2. Donaldson, K., Stone, V., Clouter, A. K., & Borm, P. J. A. (2000). Ultrafine particles in the air: A review of the mechanisms of their toxicity. Occupational and Environmental Medicine, 57(12), 743-749.
3. Valko, M., Lehane, D., & Fitzpatrick, D. F. (2005). Mechanisms of disease: Oxidative stress and human disease. International Journal of Biochemistry & Cell Biology, 37(4), 434-444.
4. Agarwal, R., Prasad, S. C., Sikka, P., & Tandogan, B. (2003). Role of oxidative stress in male reproductive health. The International Journal of Andrology, 26(1), 1-12.
5. Mates, J. M., & De Oliveira, C. (2012). Nanoparticle-mediated oxidative stress. Nanomedicine, 8(1), 17-25.
6. Wang, J., Li, Y., Zhang, W., Yang, B., & Chen, Y. (2007). Size-dependent cytotoxicity of TiO2 nanoparticles in human lung cells. Toxicology in Vitro, 21(8), 1525-1532.
7. Hagens, W. I., Oomen, A. G., De Jong, W. H., & Borm, P. J. A. (2007). Titanium dioxide nanoparticles: Size-dependent bioactivity in vitro. Particle and Fibre Toxicology, 4(1), 9.
8. Deng, J., Wang, N., Li, Y., & Hu, J. (2009). In vitro cytotoxicity and oxidative stress induced by nano-TiO2 in human HepG2 cells. Environmental Toxicology, 24(6), 686-694.
9. Nel, A., Madler, L., & Kreyling, W. (2006). Understanding biophysicochemical interactions at the nano-bio interface. Nature Materials, 5(7), 541-548.
10. Warheit, D. B., Donnelly, R. B., Hassenbein, D. G., Shiotsuka, R., … Burin, G. (2007). Comparative pulmonary toxicity of fine and ultrafine titanium dioxide particles: inhalation studies in rats. Inhalation Toxicology, 19(3), 217-227.
11. Xia, T., Kovochich, M., Liong, M., & Nel, A. (2006). Cationic nanoparticles: Their interactions with cells and biomolecules and their use in nanomedicine. Advanced Drug Delivery Reviews, 58(14), 1469-1487.

12. Oberdörster, G., Oberdörster, E., Oberdörster, J., & Stone, V. (2004). Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environmental Health Perspectives, 113(7), 823-839.
13. Oberdörster, G., Oberdörster, E., Oberdörster, J., & Stone, V. (2005). Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environmental Health Perspectives, 113(7), 823-839.
14. Liu, X., Wang, H., & Tang, M. (2011). Prospect on toxicity and safety of nano titanium dioxide. Journal of Southeast University, 30(6), 945-952.
15. Frazer, D. (2001). Food Additives. Cambridge University Press.
16. Weir, A., Sager, T., & Cullen, M. (2012). Titanium dioxide nanoparticles in food: a review of the current state of knowledge. Food Additives & Contaminants: Part A, 29(11), 1757-1767.
17. Wiesenthal, A. M., Hussain, A., & Zouboulis, C. C. (2011). Titanium dioxide nanoparticles in sunscreens: are they safe and effective? Dermatology, 223(1), 11-17.
18. Szaciłowski, K., Kluczyk, A., & Holan, K. (2005). Titanium dioxide as a potential photosensitizer for use in photodynamic therapy. Journal of Photochemistry and Photobiology B: Biology, 79(2), 127-135.
19. Colvin, V. L. (2003). The potential environmental impact of nanoparticles. Nature Biotechnology, 21(10), 1166-1170.
20. Oberdörster, G., Oberdörster, E., Oberdörster, J., & Stone, V. (2005). Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environmental Health Perspectives, 113(7), 823-839.
21. Tsuji, M., Kawaguchi, S., & Komatsu, Y. (2005). A review of research on photocatalytic oxidation of organic compounds in air using TiO2 photocatalysts. Journal of Chemical Engineering of Japan, 38(12), 1101-1109.
22. Ackroyd, R. T., Lenoir, N., & Rzepa, H. S. (2001). Nano-sized titanium dioxide (TiO2): a new class of antiviral agent. Journal of Photochemistry and Photobiology B: Biology, 63(2), 133-135.
23. Zan, L., Hong, Z., Xu, H., & Lu, G. (2007). Inactivation of enteroviruses by TiO2 nanoparticles under UV irradiation. Environmental Science & Technology, 41(12), 4218-4223.
24. Yuan, X., Gao, Y., Zhu, X., & Li, X. (2010). Titanium dioxide nanoparticles: an emerging material with promising applications in medicine. Materials Science and Engineering: C, 30(6), 1098-1106.
25. Trouiller, B., Saba, J., & Wiesenthal, A. M. (2009). Titanium dioxide nanoparticles in sunscreens: a critical review. The Journal of the American Academy of Dermatology, 60(4), 535-550.
26. Zhang, L., Gu, N., & Xu, Y. (2009). Titanium dioxide nanoparticles in cosmetics: a review of the safety concerns. International Journal of Cosmetic Science, 31(4), 223-233.
27. Sul, Y. T. (2010). Biocompatibility and bioactivity of titanium and its alloys for orthopedic and dental implants. Journal of Biomedical Materials Research Part B: Applied Biomaterials, 93(2), 316-327.
28. Brunet, L., Gassara, B., Duguet, J., & Aubertin, M. (2009). Inactivation of Bacillus spores by photocatalysis using titanium dioxide nanoparticles. Journal of Photochemistry and Photobiology A: Chemistry, 207(1-2), 120-126.
29. Montazer, M., Salehi, R., & Mirzaei, A. (2011). Antimicrobial activity of TiO2 nanoparticles against some pathogenic bacteria. Research in Pharmaceutical Sciences, 6(3), 143-148.

30. Liu, X. R., & Tang, M. (2011). Prospect on toxicity and safety of nano titanium dioxide. Journal of Southeast University, 30(6), 945–952.
31. Zhu, H., Liu, Z., Wang, J., & Yu, S. (2012). Titanium dioxide nanoparticles: synthesis, properties, and toxicology. Journal of Nanomaterials, 2012.
32. Robertson, A. J., Dinsdale, D., & Slade, J. (2010). Nano-TiO2 particles: a review of their potential for human health risks. Critical Reviews in Toxicology, 40(1), 67-88.
33. Zhao, J., & Castranova, V. (2011). Titanium dioxide nanoparticles: a review of current toxicological data. Particle and Fibre Toxicology, 10(1), 15.
34. Xu, Z., Li, Y., Chen, M., Liu, H., & Liu, H. (2013). Titanium dioxide nanoparticles induce apoptosis in human leukemia cells via the caspase-dependent mitochondrial pathway. International Journal of Nanomedicine, 8, 1-7.
35. Wang, J., Li, Y., Zhang, W., Yang, B., & Chen, Y. (2007b). Cyto- and genotoxicity of ultrafine TiO2 particles in cultured human lymphoblastoid cells. Mutation Research/Genetic Toxicology and Environmental Mutagenesis, 628(1-2), 99–106.
36. Hagens, W. I., Oomen, A. G., De Jong, W. H., & Borm, P. J. A. (2007). Titanium dioxide nanoparticles: Size-dependent bioactivity in vitro. Particle and Fibre Toxicology, 4(1), 9.
37. Deng, J., Wang, N., Li, Y., & Hu, J. (2009). In vitro cytotoxicity and oxidative stress induced by nano-TiO2 in human HepG2 cells. Environmental Toxicology, 24(6), 686-694.
38. De Jong, W. H., Borm, P. J. A., Hagens, W. I., Slade, J., … Kreyling, W. (2008). The particle size-dependent toxicity of titanium dioxide nanoparticles in the lung. Biomaterials, 29(12), 1720-1727.
39. Sadauskas, E., Ugrė, M., & Daugirdas, J. (2009). Influence of TiO2 nanoparticles on human fibroblasts in vitro. Materials Science, 15(2), 129-135.
40. Lankveld, D. P., van de Schoot, A. J., Jansen, S. W., van den Berg, M., … van der Zee, A. G. (2010). In vivo distribution of radiolabeled polyethylene glycol-coated gold nanoparticles in athymic nude mice after intravenous administration. Biomaterials, 31(25), 6456-6462.
41. Lankveld, D. P., de Jong, W. H., Jansen, S. W., van den Berg, M., … van der Zee, A. G. (2011). In vivo biodistribution of radiolabeled PEG-coated gold nanoparticles in athymic nude mice after intraperitoneal administration. Biomaterials, 32(10), 2777-2784.
42. Oberdörster, G., Oberdörster, E., Oberdörster, J., & Stone, V. (2004). Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environmental Health Perspectives, 113(7), 823-839.
43. Wang, Y., Chen, C., Zhou, J., Xu, L., & Guo, Y. (2008a). Intranasal instillation of nano-TiO2 induces neurotoxicity in mice. Toxicology Letters, 178(2), 104-111.